Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

2025-03-31 15:03:48 ET

Summary

• Sellas Life Sciences Group, Inc.'s stock has dropped significantly, with a Hold rating due to uncertainty around the final Phase 3 trial data for GPS in AML.
• Interim results for GPS are promising but inconclusive; the trial continues until 80 patients die, creating investment uncertainty and ongoing cash burn.
• The company raised $25M in January 2025, extending its runway to late 2025, but may need more funds for regulatory and commercial plans.
• Current SLS shareholders should hold steady and consider accumulating if the stock dips below $1/share, given the potential for exponential upside if GPS succeeds.

SELLAS Life Sciences Group, Inc. ( SLS ) remains in a holding pattern. Shares have dropped around 13% over the last six months, and significantly more from its 2024 highs....

Read the full article on Seeking Alpha

For further details see: